Search Results

Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases. The deal reflects a broader industry shift toward platform-based genetic medicine partnerships, where large pharma increasingly secures access to modular, early-stage technologies rather than individual assets, in order to expand therapeutic reach across high-unmet-need disease areas. A Platform Deal Built Around RNA Exon Editing The collaboration centres on RNA exon editing, a post-transcriptional gene modulation approach designed to precisely modify RNA sequences without altering underlying DNA. Developed by Ascidian Therapeutics, the platform aims to: Enable highly targeted correction of disease-causing genetic errors Support potential one-time or durable therapeutic interventions Expand treatable space in monogenic and genetically defined diseases The approach is being explored across multiple therapeutic areas, including renal, neurological, retinal, and neuromuscular disorders, with this agreement initially focused on kidney disease targets. A Structured Division of Development Responsibilities Under the terms of the collaboration: Ascidian Therapeutics will: Lead target discovery Conduct selected preclinical development activities Drive early platform advancement and programme selection Eli Lilly and Company will: Hold exclusive, target-specific rights in kidney disease Lead additional preclinical development Oversee clinical development Manage manufacturing and global commercialisation This structure reflects a clear separation of innovation generation (biotech) and late-stage execution (pharma), designed to accelerate translation while managing development risk. Financial Structure and Incentive Design: The agreement includes: An undisclosed upfront payment to Ascidian Up to $1.9bn in total potential deal value, including milestones Additional tiered royalties on future product sales Milestone payments are expected to be tied to: Clinical development progress Regulatory approvals Commercial performance thresholds The structure aligns long-term incentives across both parties while maintaining flexibility for programme expansion into additional targets. Why This Deal Matters Now The Lilly–Ascidian collaboration reflects several accelerating trends in genetic medicine and pharma strategy: Platform over asset thinking. Pharma companies are increasingly investing in technologies that can generate multiple therapeutic candidates rather than single-indication drugs. RNA-based modalities are gaining traction. RNA exon editing adds to a growing toolkit of genetic medicine approaches, alongside gene editing, RNA interference, and antisense technologies. Expansion into hard-to-treat monogenic disease. Kidney disease represents a high-value, high-unmet-need area where traditional small molecules and biologics have had limited impact. Earlier-stage risk transfer models. Large pharma continues to move upstream into discovery-stage collaborations, absorbing later-stage risk in exchange for earlier access to innovation. Strategic Implications for the Industry This agreement reinforces a structural shift in how genetic medicines are being developed: Early-stage biotech platforms are becoming multi-program revenue engines rather than single-asset stories Large pharma is increasingly acting as a late-stage development and commercialisation layer for external innovation RNA-based therapeutic classes are moving from experimental to strategically investable platforms Monogenic disease areas are becoming key entry points for next-generation genetic technologies For Lilly, the deal strengthens its position in advanced genetic and precision medicine modalities. For Ascidian, it provides both validation and capital efficiency to scale a relatively young platform technology. What to Watch Next Key developments to monitor include: Identification of specific kidney disease targets under the agreement Preclinical validation of RNA exon editing durability and specificity Safety and off-target profiling in translational models Timeline to first-in-human studies Potential expansion of the platform into additional therapeutic areas within the Lilly partnership Summary The $1.9bn Lilly–Ascidian collaboration represents a strategic expansion of RNA exon editing into monogenic kidney disease, combining platform-based biotech innovation with large pharma development and commercial infrastructure. More broadly, it reflects a continued shift in global pharmaceutical R&D toward multi-program, platform-driven partnerships designed to scale genetic medicine across multiple disease areas while distributing risk across the development lifecycle. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The partnership expands a global co-development model spanning ADCs, multispecific antibodies, and early-stage oncology assets across US and China markets. Pfizer and Innovent Biologics have entered a multi-program oncology collaboration worth up to $10bn+, covering 12 cancer therapeutics and combining early-stage discovery, clinical development, and global commercialisation across a shared pipeline. The deal reflects an increasingly common pharma strategy: accessing external innovation at scale through structured partnerships that split risk, geography, and development responsibility while accelerating access to differentiated oncology mechanisms. A 12-Asset Oncology Pipeline Spanning Two Innovation Engines The collaboration includes eight early-stage assets originating from Innovent and four discovery programmes proposed by Pfizer, spanning antibody-drug conjugates (ADCs) with novel payloads and multispecific antibodies designed to enhance immune engagement. Under the agreement, Innovent will lead discovery and Phase I development, after which Pfizer will take over global development responsibilities for selected programmes. The structure enables Pfizer to access a broad early-stage pipeline while leveraging Innovent’s established oncology discovery capabilities and clinical development infrastructure. A Multi-Layered Global Development Model The financial structure includes a $650m upfront payment to Innovent, with eligibility for up to $9.85bn in milestone payments tied to development, regulatory approvals, and commercial performance. The collaboration is split across three operational models: Four programmes licensed exclusively to Pfizer globally, with Pfizer assuming full development and commercial responsibility Four programmes licensed to Pfizer ex-China, with Pfizer leading global development outside Greater China Four programmes co-developed globally, with shared development costs and profit-sharing arrangements across the US, EU, UK, and China This hybrid structure reflects a more sophisticated approach to global drug development, balancing local innovation ecosystems with multinational commercial execution. Why This Deal Matters Now The Pfizer–Innovent partnership highlights several key trends in global oncology R&D: Pharma companies are increasingly relying on structured multi-asset collaborations rather than single-asset licensing deals. China-based biotech firms are becoming central nodes in global early-stage oncology innovation ADCs and multispecific antibodies remain among the most competitive and capital-intensive therapeutic classes. Risk-sharing models are becoming standard in large-scale oncology pipelines. The deal also underscores the growing importance of China as both a source of early-stage innovation and a strategic development partner for global pharmaceutical companies. What This Means for the Industry This collaboration reflects a broader structural shift in pharma strategy: Pipeline access is replacing asset acquisition as the dominant growth model Development responsibility is increasingly segmented by geography and stage Multinational co-development structures are becoming standard in oncology Early-stage biotech innovation is increasingly globalised across US–China partnerships Pfizer’s involvement signals continued prioritisation of oncology expansion through external innovation rather than purely internal discovery. Summary The $10bn+ Pfizer–Innovent collaboration represents a major expansion in global oncology co-development, spanning 12 programmes across ADC and multispecific antibody platforms. The deal reflects a broader shift toward multi-asset, risk-sharing partnerships designed to accelerate early-stage innovation while distributing development and commercial responsibilities across global markets. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care. The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC), becoming the first immunotherapy-based combination approved in this setting. The decision was supported by Phase III POTOMAC trial data showing a 32% reduction in the risk of disease recurrence, progression, or death compared with BCG alone. With more than five years of follow-up, the Imfinzi regimen delivered sustained disease-free survival benefits while maintaining a safety profile consistent with the individual therapies, reinforcing its potential to establish a new treatment benchmark for high-risk NMIBC patients. Alert Type Regulatory Approval (FDA) Drug/Device Name Imfinzi (durvalumab) + Bacillus Calmette-Guérin (BCG) Indication BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) in adults Therapy Area(s) Oncology, Urology, Bladder Cancer, Immuno-oncology Geography United States (FDA approval) What Changed The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC. Based on the Phase III POTOMAC trial, the combination reduced the risk of high-risk disease recurrence, progression, or death by 32% compared with BCG alone, becoming the first approved immunotherapy combination in this setting. Clinical Relevance The approval introduces a new treatment paradigm for high-risk NMIBC by adding immunotherapy to the long-established BCG backbone. The regimen demonstrated durable disease-free survival benefits over more than five years of follow-up while maintaining a manageable safety profile, preserving BCG treatment completion rates, and not negatively affecting patient-reported quality of life. Source Link https://www.globaldata.com/newsletter/details/fda-approves-astrazeneca-s-imfinzi-bcg-combination-for-nmibc-therapy_383859/ Date 1-Jun-2026 Status Draft Notes POTOMAC Phase III data showed a disease-free survival hazard ratio of 0.68 with a median follow-up of 60.7 months. No new safety signals were identified versus the known profiles of Imfinzi and BCG. Regulatory reviews are ongoing in the EU, Japan, and other markets. The approval further expands Imfinzi’s role across the bladder cancer treatment pathway alongside ongoing Phase III programmes including VOLGA, NIAGARA, and NILE. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Daraxonrasib, KRAS G12D, and the ASCO26 Signal That Broke a Long Silence At ASCO26, there are always moments the field remembers. Some are technical milestones. Some are survival curves. And occasionally, there is something more difficult to quantify — a collective reaction that tells you the data has crossed from analysis into belief. The presentation of new results in metastatic pancreatic cancer involving daraxonrasib appeared to land in that category. Reports from the room describe standing ovations, not as theatre, but as release — after years of incremental progress in a disease that has resisted almost every meaningful therapeutic advance. This article breaks down what was presented, why it matters, and how the wider oncology ecosystem is interpreting it. The Disease That Has Defined “Unmet Need” for Decades Pancreatic cancer remains one of the most challenging solid tumours in oncology. Despite advances across other cancer types, PDAC has been defined by: Late-stage diagnosis in most patients Rapid clinical deterioration Limited response durability to chemotherapy Few actionable molecular targets with proven clinical impact For years, the phrase “modest improvement” has been the dominant language of pancreatic cancer progress. ASCO26, at least in this dataset of reactions and commentary, is being framed differently. KRAS G12D: The Target That Defined the Limits of Oncology A key scientific anchor in this story is KRAS G12D, a mutation present in a substantial proportion of pancreatic cancers. Biologically, KRAS sits upstream in a signalling cascade that drives: Cell proliferation Survival signalling Metabolic adaptation Tumour persistence under therapeutic pressure For decades, KRAS was labelled “undruggable” — not because it was unimportant, but because it was structurally difficult to inhibit in a clinically meaningful way. That framing has been slowly eroded over recent years. What ASCO26 adds, according to multiple reports, is a more concrete step: evidence of clinically meaningful impact in a large, difficult-to-treat population. What the Data Is Showing Across commentary and referenced subgroup data, several consistent signals emerge: In previously treated KRAS-mutant populations, response rates around ~35% have been reported in early analyses Median duration of response cited at approximately 8 months in some subgroups Overall survival benefit described by attendees and commentators as clinically significant versus chemotherapy, with some describing it as approaching a doubling effect (final peer-reviewed confirmation pending) The key distinction here is not just response, but durability in a disease where durability has historically been rare. Importantly, these results are being associated with the investigational agent daraxonrasib, suggesting a broader shift in how KRAS-driven biology may now be therapeutically addressed. Why This Moment Feels Different What stands out in the ASCO26 reaction data is not only what was presented, but how it was received. Across clinicians, researchers, industry leaders, and patient advocates, a few phrases repeat: “historic” “breakthrough” “goosebumps” “long overdue” “standing ovation moment” This matters because oncology conferences typically reward restraint. Emotional convergence at scale usually signals that something has shifted from incremental to directional. In other words, the reaction itself becomes a secondary dataset. The Patient Layer: Why the Science Landed Emotionally One of the most striking aspects of the discourse is how frequently patients and families are present in the narrative — not abstractly, but directly. Several themes appear repeatedly: Patients who participated in early trials now represented in later success narratives Families linking scientific progress to personal loss or survival Hope framed not as abstract optimism, but as additional time: months, milestones, memories In pancreatic cancer specifically, where prognosis has often been measured in short timeframes, even incremental gains carry disproportionate emotional weight. That is part of why the reaction was not purely scientific. Where This Leaves the Field If these findings hold through full peer-reviewed publication and regulatory validation, the implications are significant: 1. KRAS is no longer a theoretical target class It is becoming a clinically actionable pathway in PDAC. 2. Pancreatic cancer treatment may be entering a stratified era Biomarker-driven therapy (including KRAS subtyping) moves from research concept to practical decision layer. 3. Competitive oncology pipelines will accelerate Success in KRAS G12D inevitably increases pressure across: RAS pathway programmes Combination immunotherapy strategies Earlier-line intervention studies What Still Needs to Be Proven Despite the strength of the signal, several questions remain open: How durable are the survival benefits at full population scale? How does toxicity compare to standard chemotherapy over time? Will efficacy extend across broader KRAS-driven tumour types? Can this be moved earlier in treatment lines with maintained benefit? These are not minor details — they determine whether this becomes a practice-changing therapy or a high-impact niche advance. A Measured Interpretation of a High-Emotion Moment ASCO26, in this dataset, is being described as a turning point. Whether it ultimately becomes one will depend on what emerges in full publication, regulatory review, and real-world use. But the current signal is clear enough to justify attention: For a disease long defined by stagnation, any consistent, meaningful survival signal in KRAS G12D pancreatic cancer is structurally important. And that is why the reaction in the room — scientific, emotional, and collective — is itself part of the story. Not because emotion replaces evidence. But because sometimes, it reflects the moment evidence begins to feel like change. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Alnylam Pharmaceuticals has entered a collaboration worth up to $2bn with Inceptive Nucleics, combining RNA interference (RNAi) drug development expertise with generative AI models specifically designed for sequence-based medicines. The partnership reflects a growing shift across biopharma: moving AI beyond administrative efficiencies and into the core scientific process of therapeutic design, where machine learning is increasingly being used to identify, optimise, and prioritise drug candidates before they reach the laboratory. Bringing Generative AI Into RNA Medicine Design Under the agreement, Alnylam will pay Inceptive $30m upfront through a combination of cash and equity investment, while the AI company becomes eligible for additional preclinical, regulatory, and commercial milestone payments that could bring the total deal value to approximately $2bn. The collaboration centres on Inceptive’s foundation models, which have been trained specifically on biological sequence data and are designed to generate insights across RNA-based therapeutic platforms. Unlike many AI systems that require extensive retraining for new applications, Inceptive’s models are designed to learn biological patterns directly from sequence data and adapt across different therapeutic modalities. The companies believe this capability could significantly reduce the time required to identify and optimise new RNAi candidates. Optimising siRNA Development at Scale The focus of the collaboration is the development of small interfering RNA (siRNA) therapeutics, a modality that forms the foundation of Alnylam’s commercial portfolio. Together, the companies aim to: Model target messenger RNA (mRNA) structures and behaviours Explore large sequence spaces to identify promising siRNA candidates Evaluate chemical modifications that could improve potency and durability Predict therapeutic performance before laboratory testing Prioritise the most promising molecules for further development The objective is not simply to generate more candidates, but to improve candidate quality earlier in the development process, reducing costly experimental cycles and increasing the probability of success. Why AI Is Becoming Central to Drug Discovery Drug discovery increasingly involves navigating enormous biological search spaces that are difficult to explore using conventional experimental methods alone. The challenge is particularly acute in RNA medicine, where therapeutic performance can be influenced by complex interactions between sequence design, target biology, delivery mechanisms, and chemical modifications. AI systems are increasingly being positioned as a solution to this complexity. Rather than relying solely on iterative laboratory testing, companies are using foundation models to predict which molecular designs are most likely to succeed before significant resources are committed. This approach has the potential to shorten development timelines, improve productivity, and reduce the cost of early-stage R&D. A Significant Milestone for Inceptive The agreement represents Inceptive’s first publicly disclosed biopharmaceutical partnership since the company emerged from stealth and raised $100m in financing. The company was founded by Jakob Uszkoreit, a former Google AI researcher who helped develop the Transformer architecture, the breakthrough innovation that underpins modern large language models including ChatGPT. Inceptive’s core thesis is that biological systems contain patterns of complexity that can be learned and modelled through large-scale AI systems in much the same way language models learn linguistic structures. The Alnylam partnership provides one of the clearest commercial validations of that approach to date. What This Means for the Industry The collaboration highlights several broader trends reshaping pharmaceutical R&D: AI is moving from workflow automation into core scientific decision-making Foundation models are increasingly being trained specifically for biological applications RNA therapeutics remain a major area of investment following the commercial success of RNA-based medicines Pharma companies are seeking AI partnerships that directly impact pipeline productivity Early-stage drug design is becoming increasingly computational before laboratory validation The deal also reflects growing confidence that AI can contribute tangible value not just in identifying drug targets, but in designing the therapeutic molecules themselves. Summary The $2bn Alnylam–Inceptive partnership represents one of the most significant recent examples of AI being integrated directly into therapeutic discovery. By combining Alnylam’s RNAi expertise with Inceptive’s sequence-focused foundation models, the companies aim to accelerate the design and optimisation of siRNA medicines while reducing the time and cost associated with traditional discovery processes. More broadly, the deal signals a shift in pharmaceutical R&D where AI is increasingly becoming a core component of how new medicines are designed, selected, and advanced into development. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

ResMed has completed its $340m acquisition of Noctrix Health, adding a newly approved neurostimulation therapy for restless leg syndrome (RLS) to its growing sleep medicine portfolio. The deal brings Noctrix’s flagship product, Nidra, into ResMed’s ecosystem and signals a broader shift in sleep medicine: expanding beyond respiratory disorders into adjacent neurological and sleep-related conditions that affect millions of patients worldwide. For ResMed, the acquisition represents an opportunity to deepen its presence across the sleep care continuum while diversifying beyond its traditional strength in sleep apnoea treatment. Adding a New Category to Sleep Medicine Noctrix’s lead product, Nidra, is a non-pharmacological therapy designed for patients with restless leg syndrome who have not responded adequately to medication. The system consists of wearable cuffs positioned below the knee that deliver mild electrical stimulation to the peroneal nerves. This approach, known as tonic motor activation (TOMAC), activates neural pathways associated with voluntary movement, helping to reduce the uncomfortable sensations and involuntary muscle activity commonly experienced by patients with RLS. Unlike traditional pharmaceutical treatments, Nidra aims to address symptoms without introducing additional drug burden, an increasingly attractive proposition as healthcare systems look to reduce long-term medication dependency. The therapy received de novo clearance from the US Food and Drug Administration in 2023, establishing a new regulatory category for the treatment. A Large and Underserved Patient Population Restless leg syndrome remains one of the most common sleep-related neurological disorders. Research from the American Academy of Sleep Medicine suggests that approximately 13% of Americans report having been diagnosed with the condition. Despite its prevalence, treatment options remain relatively limited, particularly for patients who fail to respond to existing pharmaceutical therapies or experience undesirable side effects. The acquisition gives ResMed access to a sizeable patient population that overlaps significantly with its existing sleep-focused customer base. This creates potential opportunities for integrated diagnosis, treatment, and patient management across multiple sleep disorders. Building a Broader Sleep Health Platform ResMed has historically been best known for its leadership in sleep apnoea treatment through products such as the AirSense continuous positive airway pressure (CPAP) platform. The company also maintains a significant respiratory care business through products including the Astral and Stellar ventilator systems. Adding Nidra extends ResMed’s portfolio into neurostimulation-based sleep therapies and reflects a wider industry trend towards building comprehensive disease ecosystems rather than focusing on individual products. Rather than competing solely within the sleep apnoea market, ResMed is increasingly positioning itself as a broader sleep health company capable of addressing multiple conditions that impact sleep quality and long-term patient outcomes. A Milestone Exit for Angelini Ventures The acquisition also represents the first successful exit for Angelini Ventures, the corporate venture capital arm of Angelini Industries. Launched in 2022 with an initial €300m investment commitment, the fund focuses on biotechnology, medtech, and digital health companies addressing significant unmet medical needs. Angelini participated in Noctrix's $40m Series C financing round in 2022, supporting the company through the final stages of clinical development and commercialisation. The transaction provides an early validation of the fund’s investment strategy and demonstrates continued investor appetite for differentiated medical device companies with strong clinical evidence and regulatory approval. Why This Deal Matters Now The ResMed–Noctrix acquisition highlights several important trends across healthcare and medtech: Non-pharmacological therapies are gaining traction as alternatives to chronic drug treatment. Neurostimulation technologies are expanding beyond traditional neurological applications into sleep medicine. Sleep health is evolving into a broader therapeutic category encompassing multiple disorders. Medtech companies are increasingly acquiring adjacent technologies to create integrated patient ecosystems. Investors continue to reward clinically validated devices that address large unmet patient populations. The transaction also reflects growing recognition that sleep disorders rarely exist in isolation, creating opportunities for companies that can offer comprehensive solutions across diagnosis, treatment, and ongoing patient management. What This Means for the Industry The acquisition signals an important shift in how sleep medicine is developing. Historically dominated by respiratory therapies and pharmaceuticals, the market is increasingly incorporating wearable technologies, neurostimulation devices, and digital health solutions. As healthcare providers seek more personalised and less invasive treatment approaches, therapies such as TOMAC may become an increasingly important part of the sleep medicine toolkit. For ResMed, the acquisition expands both its addressable market and its ability to support patients across a wider range of sleep-related conditions. Summary ResMed’s $340m acquisition of Noctrix Health brings FDA-authorised TOMAC therapy for restless leg syndrome into one of the world's largest sleep medicine platforms. Beyond adding a single product, the deal reflects a broader evolution in sleep healthcare, where companies are moving beyond individual disorders to build integrated ecosystems capable of treating multiple conditions that affect sleep quality and patient wellbeing. As non-drug therapies continue to gain momentum, the acquisition positions ResMed to play a larger role in the future of comprehensive sleep health management. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Philips has received FDA 510(k) clearance for Elevate Plus, an AI-enabled upgrade to its EPIQ Elite and Affiniti ultrasound systems, alongside CE mark approval in Europe. The update brings a clear strategic message: ultrasound is no longer just an imaging modality — it is becoming an AI-assisted workflow platform designed to standardise clinical decision-making at scale At its core, Elevate Plus combines automation, image enhancement, and embedded decision support tools to reduce variability in routine examinations and improve consistency across operators and care settings. Moving From Imaging to Intelligent Workflow Ultrasound has traditionally been highly operator-dependent, with image quality and interpretation varying significantly based on clinician experience. Philips is positioning Elevate Plus as a response to that challenge. The upgrade introduces AI-driven workflow automation features designed to streamline routine exams and reduce the need for repeat scans, particularly in high-volume clinical environments. A key component is Auto Measure Abdomen, an AI tool that automates common abdominal measurements during scanning. Philips reports accuracy rates above 93% when compared with manual expert readings, suggesting a growing level of reliability in automated clinical measurement. The objective is not to replace clinicians, but to reduce repetitive tasks and minimise variation in routine workflows. AI Decision Support Moves Onto the Ultrasound Cart A notable shift with Elevate Plus is the integration of Koios AI decision support tools directly on-cart within the ultrasound systems. Previously, these tools were only available off-cart and limited to Philips-generated images. Now, clinicians can perform real-time lesion classification during the scan itself, including: ~ Breast lesion classification using Koios BI-RADS Thyroid nodule assessment using Koios TI-RADS These models are trained on large datasets of pathology-confirmed cases, enabling rapid risk stratification at the point of imaging. This shift brings AI closer to the point of clinical decision-making, rather than treating it as a downstream analytical tool. Enhancing Image Quality With AI-Based Processing Alongside workflow automation, Elevate Plus introduces new imaging enhancements designed to improve clarity and diagnostic confidence. These include: XRes Pro+: enhancing tissue detail and boundary definition Super Res MVI Pro: improving microvascular flow visualisation Together, these tools aim to make subtle anatomical and vascular features easier to interpret, particularly in complex or fast-paced clinical environments. The emphasis is on consistency — ensuring that image quality is less dependent on operator skill and more standardised across systems and users. Why This Matters for Clinical Imaging Ultrasound sits at the intersection of high clinical utility and high variability. It is widely used, relatively low-cost, and highly versatile — but historically dependent on operator expertise for both image acquisition and interpretation. AI-enabled systems like Elevate Plus represent a shift toward: Standardised imaging quality across healthcare settings Reduced repeat scanning and improved workflow efficiency Earlier integration of diagnostic support during the exam itself Greater consistency in high-volume diagnostic environments As healthcare systems face increasing demand, these efficiency gains become structurally important rather than merely incremental improvements. A Broader Strategic Direction in Medical Imaging Philips’ latest clearance reflects a wider industry trend: imaging platforms are evolving into integrated diagnostic ecosystems. Rather than separate tools for acquisition, analysis, and interpretation, companies are increasingly embedding AI directly into imaging hardware to support real-time decision-making. This moves ultrasound closer to a fully assisted diagnostic workflow, where automation supports clinicians throughout the entire examination process. Summary The FDA clearance of Philips’ Elevate Plus marks another step in the evolution of ultrasound from a manual imaging tool to an AI-powered diagnostic workflow platform. By combining automated measurements, embedded decision support, and enhanced imaging quality, Philips is aiming to reduce variability, improve efficiency, and support more consistent clinical outcomes across high-demand healthcare environments. More broadly, the upgrade highlights a clear direction for medical imaging: tighter integration between AI, hardware, and clinical decision-making at the point of care. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Roche has struck a deal worth up to $2.3bn with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an oral BTK degrader targeting B-cell malignancies, immunology, and neurology. The move signals a deeper strategic shift in the BTK space — from inhibition to degradation — as pharma companies look to overcome resistance mechanisms and expand therapeutic durability in complex blood cancers. Moving Beyond BTK Inhibition BTK has long been a validated target in haematology and immune-mediated diseases, with multiple oral inhibitors already on the market or in late-stage development. But degraders represent a step change. Rather than simply blocking BTK activity, bexobrutideg is designed to eliminate the protein entirely, offering a potentially more complete and durable therapeutic effect. Early clinical data has shown promising single-agent activity in diseases such as: Chronic lymphocytic leukaemia (CLL) Waldenström macroglobulinaemia A Phase III study in relapsed/refractory CLL is expected to begin this summer, where the drug will be evaluated against Eli Lilly’s BTK inhibitor Jaypirca (pirtobrutinib), setting up a key head-to-head benchmark in the class. A Multi-Asset, Shared-Risk Structure The Roche–Nurix collaboration is structured as a fully integrated co-development and co-commercialisation agreement: $700m upfront payment to Nurix Up to $2.3bn total deal value including milestones 60/40 cost sharing on development (Roche/Nurix) 50/50 split of US profits and losses Roche leads commercialisation outside the US Nurix eligible for tiered royalties in international markets This model reflects a broader industry trend: pharma is increasingly willing to share both risk and upside in exchange for earlier access to differentiated science. Why Roche Is Moving Now Roche already has a BTK franchise strategy in motion, including fenebrutinib, an oral BTK inhibitor in development for multiple sclerosis. But the competitive landscape is intensifying: New-generation BTK inhibitors are already on the market Multiple competitors are advancing next-gen molecules BTK degraders are emerging as a potential next wave of innovation By partnering early in the degrader space, Roche is effectively hedging its BTK future while expanding optionality across haematology, immunology, and neurology. From Blocking to Degrading: A Platform Shift What makes this deal notable is not just the asset, but the modality. BTK degraders represent part of a wider movement in drug discovery: Moving from inhibition → degradation From reversible binding → targeted protein elimination From single-pathway modulation → broader biological control If successful, this approach could reshape how a range of disease-driving proteins are targeted beyond BTK. A Strategic Inflection Point for Nurix For Nurix, the deal validates its emerging position in targeted protein degradation — one of the most closely watched modalities in biotech. The company has signalled ambitions to evolve beyond a single-asset story into a commercial-stage player, and the Roche partnership provides: Global development scale Late-stage clinical acceleration Commercial infrastructure beyond the US Combination potential with Roche’s B-cell franchise Summary The $2.3bn Roche–Nurix collaboration marks a significant escalation in the BTK space, as the industry begins shifting from inhibition-based therapies toward next-generation protein degraders. With Phase III development imminent and head-to-head competition already emerging, Bexobrutideg is positioned at the centre of what could become a defining class evolution in haematology and immunology. More broadly, the deal reinforces a clear trend in pharma strategy: platform science + shared risk + modality innovation = the new blueprint for late-stage pipeline building. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

GSK has agreed to acquire Nuvalent in a $10.6bn all-cash transaction, bringing a trio of late-stage lung cancer assets into its oncology portfolio and marking one of the company’s largest strategic moves in over a decade. The acquisition centres on Nuvalent’s targeted therapies for genetically defined non–small-cell lung cancer (NSCLC), including ROS1 inhibitor zidesamtinib (NVL-520) and ALK inhibitor neladalkib (NVL-655), both of which are already in late-stage development and under FDA review. The deal signals a decisive pivot back toward larger, near-commercial oncology assets — a contrast to GSK’s recent preference for smaller bolt-on acquisitions in the $2–4bn range. A Multi-Asset Late-Stage Oncology Expansion Rather than a single-asset bet, the Nuvalent acquisition effectively brings a bundled late-stage pipeline into GSK’s oncology franchise. The key assets include: Zidesamtinib (ROS1 inhibitor), targeting TKI-pretreated ROS1-positive NSCLC Neladalkib (ALK inhibitor), targeting ALK-positive NSCLC NVL-330, a brain-penetrant HER2-selective TKI in early clinical development Both lead programmes are already supported by Phase I/II data and have FDA decisions pending later this year, with potential launches depending on regulatory outcomes. Zidesamtinib has shown objective response rates in the mid-40% range in heavily pre-treated populations, with higher efficacy in patients exposed to fewer prior therapies. Neladalkib has demonstrated response rates in the low 30% range in similar settings. Together, these assets strengthen GSK’s position in molecularly defined lung cancers where sequential resistance to existing tyrosine kinase inhibitors continues to create unmet clinical need. A Strategic Shift in Capital Deployment GSK CEO Luke Miels described the transaction as a “multi-product deal” targeting clinically validated mechanisms that address both efficacy and tolerability gaps in lung cancer treatment. While the company had previously signalled a preference for smaller, modular acquisitions, Miels noted that Nuvalent represented a “three-in-one” opportunity that justified a larger upfront commitment. The $124 per share cash offer represents a 40% premium to Nuvalent’s closing price on June 8, with the transaction expected to close in Q3, pending regulatory approval. Why This Deal Matters Now The acquisition highlights several broader trends shaping oncology M&A: Pharma is increasingly prioritising late-stage, de-risked oncology assets over early discovery platforms Molecularly targeted lung cancer therapies remain one of the most competitive and commercially attractive areas in oncology Large-cap pharma is re-accelerating deal size after a period of capital discipline Multi-asset acquisitions are re-emerging as a way to compress pipeline risk and time-to-market Importantly, timing also matters. With FDA decisions for both lead assets expected imminently, GSK is positioning itself not just for pipeline expansion, but for potential near-term commercial launches. A Platform for Broader Lung Cancer Growth Beyond the acquired assets, GSK expects the deal to reinforce its broader oncology strategy, including internal development of its B7-H3 antibody-drug conjugate programme risvutatug rezetecan in small-cell lung cancer. Analysts have suggested the acquisition could also help offset longer-term revenue pressures from upcoming patent expirations in other therapeutic areas by strengthening GSK’s oncology revenue base. Summary The $10.6bn acquisition of Nuvalent represents a significant escalation in GSK’s oncology strategy, bringing multiple late-stage lung cancer therapies into its pipeline at a pivotal moment for regulatory and commercialisation timelines. More broadly, the deal reflects a renewed industry preference for late-stage, multi-asset acquisitions designed to accelerate near-term revenue generation while reinforcing long-term therapeutic platforms in high-value oncology markets. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Eli Lilly has signed a licensing deal worth up to $1bn with Swedish biotech AlzeCure Pharma for ACD680, a preclinical Alzheimer’s programme targeting amyloid-beta production via gamma-secretase modulation. The move extends Lilly’s growing presence in Alzheimer’s disease and adds a complementary approach to its existing anti-amyloid therapy Kisunla (donanemab), shifting part of its focus further upstream in disease biology. A Shift From Removal To Modulation ACD680 is a small molecule gamma-secretase modulator designed to alter how amyloid precursor proteins are processed. Instead of directly clearing amyloid plaques, it aims to reduce production of Aβ42, a peptide associated with plaque formation, while increasing shorter amyloid-beta fragments such as Aβ37 and Aβ38, which are considered less toxic. The concept sits within a long-standing but still active hypothesis in Alzheimer’s research: that changing amyloid production early in the disease cascade may offer a more durable disease-modifying effect. Deal Structure The agreement includes: $10m upfront payment Up to ~$990m in development and commercial milestones Mid-single digit royalties on future sales Lilly secures global rights to ACD680, while AlzeCure retains upside through milestone and royalty participation. Why This Matters For Lilly The deal strengthens Lilly’s Alzheimer’s strategy at a time when the field remains both commercially important and scientifically contested. Kisunla positioned Lilly in the anti-amyloid antibody space, but outcomes across the class continue to generate debate around the magnitude of clinical benefit in real-world settings. Despite this, amyloid remains the dominant biological target in Alzheimer’s drug development, with dozens of active programmes continuing to pursue variations of the same pathway. ACD680 represents a complementary angle rather than a replacement strategy, broadening Lilly’s exposure across multiple points in amyloid biology. Part Of A Broader Dealmaking Wave The Alzheimer’s agreement is one of several major transactions Lilly has signed in 2026, reflecting a sustained external innovation strategy across multiple therapeutic areas. Recent deals include: A $1.9bn RNA exon editing partnership with Ascidian Therapeutics A $1.26bn GLP-2 licensing deal with Hanmi Pharmaceutical A $3bn collaboration with Haisco Pharmaceutical Group $3.83bn in vaccine-related acquisitions across multiple biotech companies The pattern reflects a clear shift towards building breadth across modalities through structured, milestone-driven partnerships. Summary The $1bn AlzeCure deal reinforces Lilly’s continued commitment to Alzheimer’s disease while expanding its strategy from antibody-based plaque targeting into earlier-stage modulation of amyloid production. More broadly, it underscores how large pharma is increasingly building pipelines through layered, multi-modal external innovation rather than single-platform dependence. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Subtle Medical has received FDA clearance for SubtleHD(CT), an AI-powered software platform designed to improve computed tomography (CT) image quality by reducing noise and enhancing low-contrast detectability. The clearance marks the company's expansion beyond PET and MRI imaging enhancement, extending its AI imaging platform into one of the most widely used diagnostic modalities in healthcare. The announcement follows closely behind the company's $33m Series C financing round and highlights growing momentum behind AI-driven workflow optimisation in medical imaging. Bringing AI Enhancement to Existing CT Infrastructure SubtleHD(CT) has been developed as a software-as-a-medical-device (SaMD) that integrates directly into existing radiology workflows. Rather than requiring new imaging hardware, the platform is designed to improve image quality across a broad range of scanner fleets, including older CT systems that remain heavily utilised in hospitals and imaging centres. This approach reflects a growing trend across healthcare technology: using software to extend the useful life and performance of existing infrastructure rather than relying solely on capital-intensive equipment upgrades. For providers facing budget pressures and increasing imaging demand, AI enhancement tools offer a potential route to improving diagnostic quality without large-scale hardware replacement programmes. AI's Growing Role in Radiology Workflows SubtleHD(CT) joins a broader portfolio of AI imaging products already commercialised by Subtle Medical. The company's platform now includes: SubtlePET for PET image enhancement and workflow acceleration SubtleHD(MR) for MRI image quality improvement SubtleALIGN for automated MRI positioning and alignment SubtleSYNTH for generating MRI contrasts from existing image sequences Together, these products form part of Subtle's vendor-neutral AI Imaging Hub, designed to operate across multiple scanner manufacturers and healthcare environments. The strategy positions AI not as a standalone diagnostic tool, but as a workflow layer capable of improving image acquisition, standardisation and efficiency across the imaging pathway. Addressing Capacity Challenges in Medical Imaging The clearance also arrives against a backdrop of growing workforce pressure in radiology. Healthcare systems globally continue to face rising imaging demand while struggling to recruit sufficient numbers of radiologists and imaging specialists. According to projections from the Association of American Medical Colleges (AAMC), the United States could face a radiologist shortfall approaching 42,000 professionals by 2036. As a result, AI tools that reduce repeat scans, improve image consistency and streamline workflow efficiency are increasingly being viewed as operational necessities rather than experimental technologies. Funding and Leadership Momentum The FDA clearance follows Subtle Medical's recently completed $33m Series C financing round, which the company plans to use to accelerate product development and global commercial expansion. The financing also coincided with the appointment of new CEO Ohad Arazi, an experienced healthcare technology executive whose previous leadership roles have included positions at Change Healthcare, Zebra Medical Vision and Clarius Mobile Health. The combination of fresh capital, new leadership and regulatory momentum positions the company for broader adoption across imaging markets. Why This Matters SubtleHD(CT) reflects a broader shift in healthcare AI adoption. Rather than replacing clinicians, many of the most commercially successful AI applications are focused on improving workflow efficiency, image quality and operational capacity within existing clinical environments. Medical imaging has emerged as one of the clearest examples of this trend, where AI can help healthcare systems manage growing demand while maximising the value of existing infrastructure and workforce resources. Summary The FDA clearance of SubtleHD(CT) expands Subtle Medical's AI imaging platform into CT diagnostics, adding image enhancement capabilities to one of healthcare's most widely used imaging modalities. More broadly, the approval highlights how AI adoption in medical imaging is increasingly centred on workflow optimisation, infrastructure efficiency and clinician support as healthcare systems confront rising demand and growing workforce shortages. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

KARL STORZ has received US Food and Drug Administration (FDA) clearance for its RUBINA Lens exoscope, enabling the company to bring its near-infrared (NIR) fluorescence imaging technology into open surgical procedures. The approval extends the reach of KARL STORZ’s imaging ecosystem beyond minimally invasive surgery, allowing surgeons to access real-time fluorescence visualisation during a wider range of operations without requiring major changes to existing operating room infrastructure. Bringing Advanced Visualisation to Open Surgery The RUBINA Lens is a digital, camera-based exoscope that provides surgeons with a magnified 4K view of the surgical field displayed on a monitor. The system allows clinicians to switch between standard white-light imaging and near-infrared fluorescence imaging using indocyanine green (ICG), a fluorescent dye commonly used to assess blood flow and tissue perfusion during surgery. By combining these imaging modes, the device can reveal anatomical and physiological information that may not be visible to the naked eye, potentially supporting more informed intraoperative decision-making. The FDA clearance covers use cases including: Real-time tissue perfusion assessment Lymphatic mapping procedures Breast surgery applications Other open surgical procedures where NIR imaging with ICG may provide clinical value Expanding Existing Surgical Imaging Infrastructure One of the key advantages of the RUBINA Lens is its ability to integrate with existing KARL STORZ imaging platforms. The exoscope connects directly to the company's IMAGE1 S RUBINA systems, allowing hospitals already using KARL STORZ equipment to expand fluorescence-guided surgery capabilities without purchasing entirely new imaging infrastructure. This reflects a broader trend across surgical technology, where manufacturers are increasingly focused on extending the functionality of existing platforms rather than requiring complete equipment replacement. According to KARL STORZ, the system has been designed to fit naturally into existing operating room workflows while minimising procedural complexity. Designed for Surgical Flexibility The RUBINA Lens can be operated either as a handheld device or mounted to a holding arm, providing flexibility across different surgical environments and procedural requirements. Additional features include: High-resolution 4K imaging Wide working distance to reduce frequent refocusing Large 16:9 field of view Manual horizon control for image orientation Compatibility with standard sterilisation processes Multiple fluorescence viewing modes similar to those available in the company's endoscopic systems These capabilities are intended to support surgeon comfort while maintaining visual consistency across both open and minimally invasive procedures. Why Fluorescence-Guided Surgery Matters Fluorescence imaging has become an increasingly important tool across a growing range of surgical specialties. By using dyes such as indocyanine green, surgeons can visualise blood flow, tissue perfusion and lymphatic structures in real time, helping to identify critical anatomy and assess tissue viability during procedures. The technology has gained traction because it provides functional information beyond traditional visual inspection, offering an additional layer of data during surgery without significantly disrupting workflow. As healthcare systems continue to prioritise precision surgery and improved patient outcomes, fluorescence-guided imaging is becoming an increasingly common component of modern operating rooms. What This Means for the Industry The FDA clearance of the RUBINA Lens highlights several broader trends in surgical technology: Advanced imaging capabilities are increasingly moving beyond minimally invasive procedures into open surgery Hospitals are seeking technologies that integrate with existing operating room infrastructure Fluorescence-guided surgery continues to expand across multiple clinical specialties Digital visualisation platforms are becoming central to modern surgical workflows The approval also reinforces the growing importance of real-time imaging technologies that provide surgeons with enhanced visibility and decision support during procedures. Summary KARL STORZ has secured FDA clearance for the RUBINA Lens exoscope, extending its near-infrared fluorescence imaging capabilities into open surgery. By combining 4K visualisation with real-time fluorescence imaging and compatibility with existing KARL STORZ platforms, the device supports a growing industry shift towards image-guided surgical procedures that enhance intraoperative decision-making while fitting seamlessly into established operating room workflows. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com